Why the study?
Hand-foot syndrome is a common adverse event of lenvatinib, and dose adjustment using therapeutic drug monitoring may benefit its management.
Does serum lenvatinib concentration correlate with the severity of hand-foot syndrome in a patient with thyroid cancer?
Does serum lenvatinib concentration correlate with the severity of hand-foot syndrome in a patient with thyroid cancer?
Serum lenvatinib concentrations appear to correlate with the severity of lenvatinib-induced hand-foot syndrome, suggesting a potential role for therapeutic drug monitoring.
Authors
No takes yet. Share an insight, caveat, or question.
TDM may aid lenvatinib HFS management in select cases; leaves open whether routine monitoring improves outcomes.
Watanabe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: